05/10/2024
6:31 AM | Neurogene Inc. (Filer)
Neoleukin Therapeutics (Filer)
Neurogene Inc. (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
05/07/2024
5:20 AM | Neurogene Inc. (Filer)
Neoleukin Therapeutics (Filer)
Neurogene Inc. (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
04/26/2024
1:33 PM | Neurogene Inc. (Filer)
Neoleukin Therapeutics (Filer)
Neurogene Inc. (Filer)
| Form DEF 14A | |
04/26/2024
1:33 PM | Neurogene Inc. (Filer)
Neoleukin Therapeutics (Filer)
Neurogene Inc. (Filer)
| Form ARS | |
04/26/2024
1:34 PM | Neurogene Inc. (Filer)
Neoleukin Therapeutics (Filer)
Neurogene Inc. (Filer)
| Form DEFA14A | |
04/22/2024
3:44 PM | Neurogene Inc. (Filer)
Neoleukin Therapeutics (Filer)
Neurogene Inc. (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
04/02/2024
2:43 PM | Neurogene Inc. (Filer)
Neoleukin Therapeutics (Filer)
Neurogene Inc. (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
|
03/14/2024
7:51 PM | Cobb Stuart (Reporting)
Neurogene Inc. (Issuer)
Neoleukin Therapeutics (Issuer)
Neurogene Inc. (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
03/14/2024
7:53 PM | Cvijic Christine Mikail (Reporting)
Neurogene Inc. (Issuer)
Neoleukin Therapeutics (Issuer)
Neurogene Inc. (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
03/14/2024
7:54 PM | McMinn Rachel (Reporting)
Neurogene Inc. (Issuer)
Neoleukin Therapeutics (Issuer)
Neurogene Inc. (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
03/07/2024
3:29 PM | Babler Martin (Reporting)
Neurogene Inc. (Subject)
Neoleukin Therapeutics (Subject)
Neurogene Inc. (Subject)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
03/04/2024
5:20 PM | Neurogene Inc. (Subject)
Neoleukin Therapeutics (Subject)
Neurogene Inc. (Subject)
Smith Sean Michael (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
03/04/2024
6:30 AM | Neurogene Inc. (Filer)
Neoleukin Therapeutics (Filer)
Neurogene Inc. (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
02/20/2024
3:16 PM | Neurogene Inc. (Filer)
Neoleukin Therapeutics (Filer)
Neurogene Inc. (Filer)
| Form S-8
Registration statement under Securities Act of 1933 to be offered to employees pursuant to certain plans | |
02/14/2024
5:05 PM | EcoR1 Capital, LLC (Filed by)
Neurogene Inc. (Subject)
Neoleukin Therapeutics (Subject)
Neurogene Inc. (Subject)
| Form SC 13G | |
02/14/2024
8:19 AM | Lynx1 Capital Management LP (Filed by)
Neurogene Inc. (Subject)
Neoleukin Therapeutics (Subject)
Neurogene Inc. (Subject)
| Form SC 13G/A | |
02/09/2024
3:35 PM | Neurogene Inc. (Subject)
Neoleukin Therapeutics (Subject)
Neurogene Inc. (Subject)
SIMPSON TODD E (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
01/18/2024
5:56 PM | Neurogene Inc. (Issuer)
Neoleukin Therapeutics (Issuer)
Neurogene Inc. (Issuer)
Noonberg Sarah B. (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
01/18/2024
5:58 PM | Neurogene Inc. (Issuer)
Neoleukin Therapeutics (Issuer)
Neurogene Inc. (Issuer)
PALEKAR ROHAN (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
01/18/2024
6:01 PM | Neurogene Inc. (Issuer)
Neoleukin Therapeutics (Issuer)
Neurogene Inc. (Issuer)
Woods Robert Keith (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
01/18/2024
5:45 PM | Jordan Julie (Reporting)
Neurogene Inc. (Issuer)
Neoleukin Therapeutics (Issuer)
Neurogene Inc. (Issuer)
| Form 3
Initial statement of beneficial ownership of securities | |
01/18/2024
5:48 PM | Jordan Julie (Reporting)
Neurogene Inc. (Issuer)
Neoleukin Therapeutics (Issuer)
Neurogene Inc. (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
01/18/2024
5:51 PM | BAFFI ROBERT (Reporting)
Neurogene Inc. (Issuer)
Neoleukin Therapeutics (Issuer)
Neurogene Inc. (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
01/18/2024
5:53 PM | Freedland Cory S. (Reporting)
Neurogene Inc. (Issuer)
Neoleukin Therapeutics (Issuer)
Neurogene Inc. (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
01/05/2024
6:11 AM | Neurogene Inc. (Filer)
Neoleukin Therapeutics (Filer)
Neurogene Inc. (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
12/26/2023
5:04 PM | Freedland Cory S. (Reporting)
Neurogene Inc. (Issuer)
Neoleukin Therapeutics (Issuer)
Neurogene Inc. (Issuer)
| Form 3
Initial statement of beneficial ownership of securities | |
12/26/2023
5:05 PM | Cobb Stuart (Reporting)
Neurogene Inc. (Issuer)
Neoleukin Therapeutics (Issuer)
Neurogene Inc. (Issuer)
| Form 3
Initial statement of beneficial ownership of securities | |
12/26/2023
5:10 PM | BAFFI ROBERT (Reporting)
Neurogene Inc. (Issuer)
Neoleukin Therapeutics (Issuer)
Neurogene Inc. (Issuer)
| Form 3
Initial statement of beneficial ownership of securities | |
12/26/2023
5:10 PM | Neurogene Inc. (Issuer)
Neoleukin Therapeutics (Issuer)
Neurogene Inc. (Issuer)
Woods Robert Keith (Reporting)
| Form 3
Initial statement of beneficial ownership of securities | |
12/26/2023
5:12 PM | McMinn Rachel (Reporting)
Neurogene Inc. (Issuer)
Neoleukin Therapeutics (Issuer)
Neurogene Inc. (Issuer)
| Form 3
Initial statement of beneficial ownership of securities | |
12/26/2023
5:16 PM | Cvijic Christine Mikail (Reporting)
Neurogene Inc. (Issuer)
Neoleukin Therapeutics (Issuer)
Neurogene Inc. (Issuer)
| Form 3
Initial statement of beneficial ownership of securities | |
12/20/2023
5:43 PM | 667, L.P. (Reporting)
Baker Bros. Advisors LLC (0001580575) (Reporting)
BAKER BROS. ADVISORS LP (Reporting)
Baker Brothers Life Sciences LP (Reporting)
BAKER FELIX (Reporting)
BAKER JULIAN (Reporting)
Neurogene Inc. (Issuer)
Neoleukin Therapeutics (Issuer)
Neurogene Inc. (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
12/20/2023
4:24 PM | BAKER BROS. ADVISORS LP (Filed by)
Neurogene Inc. (Subject)
Neoleukin Therapeutics (Subject)
Neurogene Inc. (Subject)
| Form SC 13D/A | |
12/19/2023
6:31 AM | Neurogene Inc. (Filer)
Neoleukin Therapeutics (Filer)
Neurogene Inc. (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
12/06/2023
3:21 PM | Neoleukin Therapeutics, Inc. (Filer)
Neoleukin Therapeutics (Filer)
Neoleukin Therapeutics, Inc. (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
12/06/2023
3:24 PM | Neoleukin Therapeutics, Inc. (Subject)
Neoleukin Therapeutics (Subject)
Neoleukin Therapeutics, Inc. (Subject)
| Form 425 | |
12/04/2023
4:10 PM | Neoleukin Therapeutics, Inc. (Filer)
Neoleukin Therapeutics (Filer)
Neoleukin Therapeutics, Inc. (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
12/04/2023
4:14 PM | Neoleukin Therapeutics, Inc. (Subject)
Neoleukin Therapeutics (Subject)
Neoleukin Therapeutics, Inc. (Subject)
| Form 425 | |
11/13/2023
11:15 PM | Neoleukin Therapeutics, Inc. (Filer)
Neoleukin Therapeutics (Filer)
Neoleukin Therapeutics, Inc. (Filer)
| Form EFFECT | |
11/08/2023
1:34 PM | Neoleukin Therapeutics, Inc. (Filer)
Neoleukin Therapeutics (Filer)
Neoleukin Therapeutics, Inc. (Filer)
| Form S-4/A | |
10/18/2023
3:09 PM | Neoleukin Therapeutics, Inc. (Filer)
Neoleukin Therapeutics (Filer)
Neoleukin Therapeutics, Inc. (Filer)
| Form S-4/A | |
Red Alert: Your Money's Disappearance Act - Banks' Greed Unleashed! (Ad) Get your free information kit NOW, before it’s too late. Inside you’ll get the 3 secret strategies you can put in place starting today, so “they” don’t get your money tomorrow. Click here for your free guide |
10/10/2023
3:42 PM | BAKER BROS. ADVISORS LP (Filed by)
Neoleukin Therapeutics, Inc. (Subject)
Neoleukin Therapeutics (Subject)
Neoleukin Therapeutics, Inc. (Subject)
| Form SC 13D/A | |
10/10/2023
3:22 PM | 667, L.P. (Reporting)
Baker Bros. Advisors LLC (0001580575) (Reporting)
BAKER BROS. ADVISORS LP (Reporting)
Baker Brothers Life Sciences LP (Reporting)
BAKER FELIX (Reporting)
BAKER JULIAN (Reporting)
Neoleukin Therapeutics, Inc. (Issuer)
Neoleukin Therapeutics (Issuer)
Neoleukin Therapeutics, Inc. (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
10/05/2023
11:50 AM | Neoleukin Therapeutics, Inc. (Subject)
Neoleukin Therapeutics (Subject)
Neoleukin Therapeutics, Inc. (Subject)
| Form 425 | |
09/28/2023
3:28 PM | Neoleukin Therapeutics, Inc. (Filer)
Neoleukin Therapeutics (Filer)
Neoleukin Therapeutics, Inc. (Filer)
| Form S-4/A | |
09/22/2023
7:03 AM | Neoleukin Therapeutics, Inc. (Filer)
Neoleukin Therapeutics (Filer)
Neoleukin Therapeutics, Inc. (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
08/17/2023
4:08 PM | 667, L.P. (Reporting)
Baker Bros. Advisors LLC (0001580575) (Reporting)
BAKER BROS. ADVISORS LP (Reporting)
Baker Brothers Life Sciences LP (Reporting)
BAKER FELIX (Reporting)
BAKER JULIAN (Reporting)
Neoleukin Therapeutics, Inc. (Issuer)
Neoleukin Therapeutics (Issuer)
Neoleukin Therapeutics, Inc. (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
08/17/2023
4:12 PM | BAKER BROS. ADVISORS LP (Filed by)
Neoleukin Therapeutics, Inc. (Subject)
Neoleukin Therapeutics (Subject)
Neoleukin Therapeutics, Inc. (Subject)
| Form SC 13D/A | |
07/27/2023
4:15 PM | Neoleukin Therapeutics, Inc. (Subject)
Neoleukin Therapeutics (Subject)
Neoleukin Therapeutics, Inc. (Subject)
Redmile Group, LLC (Filed by)
| Form SC 13D | |
07/19/2023
4:28 PM | BAKER BROS. ADVISORS LP (Filed by)
Neoleukin Therapeutics, Inc. (Subject)
Neoleukin Therapeutics (Subject)
Neoleukin Therapeutics, Inc. (Subject)
| Form SC 13D/A | |
07/18/2023
7:34 AM | Neoleukin Therapeutics, Inc. (Filer)
Neoleukin Therapeutics (Filer)
Neoleukin Therapeutics, Inc. (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
07/18/2023
7:37 AM | Neoleukin Therapeutics, Inc. (Subject)
Neoleukin Therapeutics (Subject)
Neoleukin Therapeutics, Inc. (Subject)
| Form 425 | |
06/12/2023
11:57 AM | Neoleukin Therapeutics, Inc. (Filer)
Neoleukin Therapeutics (Filer)
Neoleukin Therapeutics, Inc. (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
